Omniscient Neurotechnology: Scaling up Clinical Connectomics SaaS Strategy and Neurotech Vision

Send us Fan MailIn this episode of the WTR Healthcare Happenings, Adam Fraser, COO of Omniscient Neurotechnology—a privately held, Australian‑based but U.S.-focused company pioneering AI‑driven brain mapping—joins Water Tower Research Co‑Founder Tim Gerdeman and Healthcare Analyst Robert Sassoon for a deep dive into the future of clinical connectomics. The discussion explores how Omniscient’s flagship platform, Quicktome, uses advanced AI to transform complex brain data into intuitive, Google‑Maps‑style network visualizations that enhance neurosurgical planning, support coma and mental‑health assessments, and inform broader brain‑care decisions. Fraser also walks through the company’s growth trajectory, funding milestones, and strategy to scale across the U.S. hospital market while laying the groundwork for global expansion and broader neurotech partnerships. The conversation concludes with Omniscient’s long‑term vision to build a comprehensive “brain data economy” capable of powering next‑generation innovations—from BCIs and DBS to emerging solutions like TMS for major psychiatric conditions.